3-37014544-C-T
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM5PP3_Strong
The ENST00000231790.8(MLH1):c.790C>T(p.His264Tyr) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.0000141 in 1,558,108 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. H264D) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000231790.8 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MLH1 | NM_000249.4 | c.790C>T | p.His264Tyr | missense_variant, splice_region_variant | 9/19 | ENST00000231790.8 | NP_000240.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MLH1 | ENST00000231790.8 | c.790C>T | p.His264Tyr | missense_variant, splice_region_variant | 9/19 | 1 | NM_000249.4 | ENSP00000231790.3 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152106Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 250062Hom.: 0 AF XY: 0.0000222 AC XY: 3AN XY: 135222
GnomAD4 exome AF: 0.0000135 AC: 19AN: 1406002Hom.: 0 Cov.: 24 AF XY: 0.0000228 AC XY: 16AN XY: 702876
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152106Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74290
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 19, 2023 | The p.H264Y variant (also known as c.790C>T), located in coding exon 9 of the MLH1 gene, results from a C to T substitution at nucleotide position 790. The amino acid change results in histidine to tyrosine at codon 264, an amino acid with similar properties. However, this change occurs in the last base pair of coding exon 9, which makes it likely to have some effect on normal mRNA splicing. RNA studies have demonstrated that this alteration does not result in abnormal splicing in the set of samples tested (Ambry internal data). In one functional study, the p.H264Y variant demonstrated restored cytotoxicity to methylation damage in a human colorectal cancer cell line; however, the mean survival score was between those of known damaging and neutral alterations leading to the tentative classification of "potentially neutral" (Bouvet D et al. Gastroenterology. 2019 08;157(2):421-431). This alteration has been reported in a Chinese male diagnosed with a MSI-H colorectal cancer at age 30y which demonstrated absent MLH1 protein expression on IHC. However, authors note that this alteration was detected in conjunction with the MLH1 p.T117M mutation, presumably on the same chromosome (in cis) as this patient's affected mother was also found to carry both alterations (Chan TL et al. J. Natl. Cancer Inst., 1999 Jul;91:1221-6; Lucci-Cordisco E et al. Cancer Biomark, 2006;2:11-27; Yuen ST et al. Oncogene, 2002 Oct;21:7585-92). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Oct 17, 2022 | This missense variant replaces histidine with tyrosine at codon 264 of the MLH1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies report conflicting results for this variant. One study assaying DNA damage tolerance found this variant to be functional (PMID: 30998989), while another study assaying DNA repair activity in mouse cells reported this variant as pathogenic (PMID: 31784484). This variant has been reported in individuals affected with colorectal cancer (PMID: 10413423, 30998989). This variant has been identified in 5/281464 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 23, 2019 | Variant summary: MLH1 c.790C>T (p.His264Tyr) results in a conservative amino acid change located in the DNA mismatch repair protein, S5 domain 2-like domain (IPR013507) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. Despite the variant being located at the last nucleotide position in exon 9, 5/5 computational tools predict no significant impact on normal splicing. Additionally, no truncated protein product was detected in a patient sample carrying the variant, supporting the lack of impact of this variant on splicing (Chan_1999). The variant allele was found at a frequency of 1.6e-05 in 250062 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.790C>T has been reported in the literature in a mother and son with colorectal cancer who also carried another pathogenic variant MLH1 c.350C>T (p.T117M), providing supporting evidence for a benign role (Chan_1999, Yuen_2002). One publication reports experimental evidence evaluating an impact on protein function, however, does not allow convincing conclusions about the variant effect (Bouvet_2019). Three submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Colorectal cancer, hereditary nonpolyposis, type 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Jul 27, 2023 | This MLH1 missense variant has been reported in a mother and son who were both affected with colorectal cancer, and both of them had a second MLH1 variant (c.350C>T; p.Thr117Met) that is known to be pathogenic. c.790C>T (rs63751597) is rare (<0.1%) in a large population dataset (gnomAD v2.1.1: 5/281464 total alleles; 0.002%; no homozygotes). It has been reported in ClinVar (Variation ID 90367). Two bioinformatic tools queried predict that this substitution would be damaging, and the histidine residue at this position is evolutionarily conserved across most of the species assessed. However, assays studying the effect of this variant on protein function have been inconclusive, with one study suggesting the variant is neutral and another suggesting a pathogenic role. While this variant changes the last nucleotide of exon 9, it is not predicted to affect normal exon 9 splicing, and at least one experimental study supports the lack of an effect on splicing. We consider the clinical significance of c.790C>T in MLH1 to be uncertain at this time. - |
Lynch syndrome 1 Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Ding PR Lab, Sun Yat-sen University Cancer Center | - | - - |
Lynch syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Mar 24, 2024 | This missense variant replaces histidine with tyrosine at codon 264 of the MLH1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies report conflicting results for this variant. One study assaying DNA damage tolerance found this variant to be functional (PMID: 30998989), while another study assaying DNA repair activity in mouse cells reported this variant as pathogenic (PMID: 31784484). This variant has been reported in individuals affected colorectal cancer (PMID: 10413423, 30998989). This variant has been identified in 5/281464 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
MLH1-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 23, 2024 | The MLH1 c.790C>T variant is predicted to result in the amino acid substitution p.His264Tyr. This variant has been reported in cis with a pathogenic MLH1 variant in a child and their mother, both with colorectal cancer (Chan et al. 1999. PubMed ID: 10413423). In vitro functional studies demonstrate a minimal effect on mismatch repair activity; however the mean survival score was potentially neutral and methylation tolerance showed minimal or no evidence of pathogenicity (Bouvet et al. 2019. PubMed ID: 30998989; Houlleberghs et al. 2019. PubMed ID: 31784484). It is interpreted as uncertain in ClinVar with multiple submitters in agreement (https://www.ncbi.nlm.nih.gov/clinvar/variation/90367/). This variant is reported in 0.0098% of alleles in individuals of South Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Oct 17, 2022 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in an individual and parent both with colorectal cancer who both also carried a pathogenic MLH1 variant (Chan et al., 1999); This variant is associated with the following publications: (PMID: 27498913, 23760103, 17192056, 12386821, 18383312, 34426522, 22753075, 21153778, 35031544, 31784484, 23403630, 10956410, 10413423, 30998989) - |
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 10, 2022 | This sequence change replaces histidine, which is basic and polar, with tyrosine, which is neutral and polar, at codon 264 of the MLH1 protein (p.His264Tyr). This variant is present in population databases (rs63751597, gnomAD 0.01%). This missense change has been observed in individual(s) with colorectal cancer (PMID: 10413423, 30998989). ClinVar contains an entry for this variant (Variation ID: 90367). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on MLH1 function (PMID: 30998989, 31784484). RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (PMID: 10413423). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Hereditary breast ovarian cancer syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | curation | German Consortium for Hereditary Breast and Ovarian Cancer, University Hospital Cologne | Jan 09, 2024 | . According to the ACMG standard criteria we chose these criteria: PM2 (supporting pathogenic): popmax:AFR popmax AF:4.82905e-05 popmax AC:2, PP3 (supporting pathogenic): CADD:29.9 REVEL: 0.911 BayesDEL:0.409449 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at